News & Updates
Filter by Specialty:
![[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC](https://sitmspst.blob.core.windows.net/images/articles/amivantamab-plus-chemo-tied-to-better-outcomes-vs-chemo-alone-in-advanced-nsclc-e2167ed1-51a8-44c8-93d2-9f1c03576b98-square.jpg)
[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC
17 Sep 2024
byStephen Padilla
Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.
[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC
17 Sep 2024
Arginine depletion plus chemo ups survival in rare lung cancer
13 Sep 2024
byAudrey Abella
In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.